{
  "ticker": "GLO",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961147",
  "id": "02961147",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1737",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0sd1lmwzc1x.pdf",
  "summary": "### Summary of ASX Announcement:  \n\n**Fund Update (Barrow Hanley Global Share Active ETF - ASX: GLOB)**  \n- **Performance (as of 31 May 2025):**  \n  - Underperformed benchmark (MSCI World Index) by **2.52%** in May, primarily due to underweights in **Information Technology** and **Communication Services**.  \n  - 1-year return: **15.63%** (fund) vs. **17.52%** (benchmark).  \n- **Top Holdings:**  \n  - Bank of Nova Scotia (3.0%), Sanofi SA (3.0%), Merck & Co. (2.9%), Rheinmetall AG (2.8%), BAE Systems plc (2.5%).  \n- **Portfolio Allocation:**  \n  - **Sectors:** Largest exposures: Financials ex-Property (18.7%), Industrials (14.0%), IT (13.3%).  \n  - **Regions:** North America (55.4%), Europe ex-UK (20.1%), UK (8.0%).  \n- **Key Commentary:**  \n  - **Rheinmetall AG** (+ve contributor): Strong defense sales growth (+73% YoY), backlog up 56% to \u20ac62B.  \n  - **Merck & Co.** (-ve contributor): Regulatory risks (U.S. drug pricing reforms) and clinical pipeline challenges.  \n  - **Sanofi SA** (-ve contributor): Pipeline setback in respiratory trials but acquired Blueprint Medicines ($9B) for immunology expansion.  \n- **Outlook:** Political/trade volatility (tariffs) and rate cut uncertainty to persist.  \n\n**No material capital markets actions (e.g., raising, corporate action) identified.**  \n\n*(Note: Excluded non-material operational/boilerplate text.)*",
  "usage": {
    "prompt_tokens": 2505,
    "completion_tokens": 388,
    "total_tokens": 2893,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T07:57:03.691816"
}